80
Participants
Start Date
December 18, 2018
Primary Completion Date
January 9, 2022
Study Completion Date
February 6, 2022
Ambrisentan
eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
Renji Hospital, Shanghai
Shanghai Zhongshan Hospital
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Xinqiao Hospital of Chongqing
OTHER
The Affiliated Hospital of Qingdao University
OTHER
First Affiliated Hospital of Chongqing Medical University
OTHER
Wuhan Asia Heart Hospital
OTHER
RenJi Hospital
OTHER